Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Vertex Pharmaceuticals Inc
Net Income (Common)
Vertex Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
-$535.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.2B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$480m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-28%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$4.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Net Income (Common)
-$278.2m
|
CAGR 3-Years
31%
|
CAGR 5-Years
21%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4.4B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
Vertex Pharmaceuticals Inc
Glance View
In the bustling landscape of biotechnology, Vertex Pharmaceuticals Inc. stands out as a dynamic powerhouse that has deftly carved a niche in the complex domain of genetic therapies. Founded in 1989, the company initially embarked on a mission to revolutionize drug discovery through a cutting-edge rational drug design approach. Armed with an innovative spirit and a focus on niche markets, Vertex turned its attention towards cystic fibrosis—a life-shortening genetic disorder affecting the lungs and digestive system. The company’s breakthrough came with the development and approval of the first therapies that address the underlying cause of cystic fibrosis, rather than just alleviating symptoms. These products, including Kalydeco and Trikafta, have repositioned Vertex from a scrappy biotech upstart to a dominating force in the drug market as these life-changing treatments not only improve patient outcomes but also command premium pricing. Vertex’s business model brilliantly capitalizes on its deep investment in research and development, allowing it to maintain a robust pipeline that promises ongoing growth. By channeling a substantial portion of its revenue back into R&D, Vertex seeks to extend its therapeutic successes beyond cystic fibrosis into other serious diseases with high unmet needs, such as sickle cell disease and beta-thalassemia. This strategic reinvestment supports a cyclical framework of innovation—capitalize on current successes while laying down the groundwork for future therapies. With a singular focus on specialty drugs that target specific genetic mutations or pathways, Vertex not only thrives on the immediate financial returns of its blockbuster drugs but continually invests in scientifically ambitious endeavors, thus reinforcing its status as a leader in the precision medicine sector.
See Also
What is Vertex Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-535.6m
USD
Based on the financial report for Dec 31, 2024, Vertex Pharmaceuticals Inc's Net Income (Common) amounts to -535.6m USD.
What is Vertex Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
3%
You don't have any saved screeners yet